KEGG   DRUG: LuspaterceptHelp
Entry
D11701                      Drug                                   

Name
Luspatercept (USAN/INN);
Luspatercept-aamt;
Reblozyl (TN)
Formula
C3350H5070N906O1044S38
Exact mass
75910.0875
Mol weight
75958.0146
Sequence
ETRECIYYNA NWELERTNQS GLERCEGEQD KRLHCYASWR NSSGTIELVK KGCWDDDFNC
YDRQECVATE ENPQVYFCCC EGNFCNERFT HLPEAGGPEV TYEPPPTGGG THTCPPCPAP
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(Disulfide bridge: 5-35, 25-53, 60-79, 66-78, 80-85, 114-114', 117-117', 149-209, 255-313, 5'-35', 25'-53', 60'-79', 66'-78', 80'-85', 149'-209', 255'-313')
  Type
Peptide
Remark
ATC code: B03XA06
Efficacy
Anti-anemic, Erythroid maturation agent
  Disease
beta Thalassemia [DS:H00228]
Comment
Treatment of anemia associated with ineffective erythropoiesis
Target
ACVR2B [HSA:93] [KO:K13596]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04350  TGF-beta signaling pathway
hsa04550  Signaling pathways regulating pluripotency of stem cells
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B03 ANTIANEMIC PREPARATIONS
   B03X OTHER ANTIANEMIC PREPARATIONS
    B03XA Other antianemic preparations
     B03XA06 Luspatercept
      D11701  Luspatercept (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor serine/threonine kinases (RSTK)
   TGFBR2 family
    ACVR2B
     D11701  Luspatercept (USAN/INN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11701
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11701
BRITE hierarchy
Other DBs
CAS: 1373715-00-4
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system